[go: up one dir, main page]

WO2006039671A3 - Gene markers of tumor metastasis - Google Patents

Gene markers of tumor metastasis Download PDF

Info

Publication number
WO2006039671A3
WO2006039671A3 PCT/US2005/035539 US2005035539W WO2006039671A3 WO 2006039671 A3 WO2006039671 A3 WO 2006039671A3 US 2005035539 W US2005035539 W US 2005035539W WO 2006039671 A3 WO2006039671 A3 WO 2006039671A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor metastasis
gene markers
markers
mouse model
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/035539
Other languages
French (fr)
Other versions
WO2006039671A2 (en
WO2006039671A9 (en
Inventor
Masato Nakamura
Yasuyuki Ohnishi
Hiroshi Suemizu
Makoto Monnai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central Institute for Experimental Animals
Original Assignee
Central Institute for Experimental Animals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/954,495 external-priority patent/US20070092881A1/en
Priority claimed from US10/955,192 external-priority patent/US20050249666A1/en
Application filed by Central Institute for Experimental Animals filed Critical Central Institute for Experimental Animals
Publication of WO2006039671A2 publication Critical patent/WO2006039671A2/en
Publication of WO2006039671A9 publication Critical patent/WO2006039671A9/en
Publication of WO2006039671A3 publication Critical patent/WO2006039671A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns the study of tumor metastasis in a NOD/SCID/Ϝcnull transgenic mouse model and the identification of tumor markers, including markers of tumors with high metastatic potential, using information obtained in this mouse model.
PCT/US2005/035539 2004-09-29 2005-09-29 Gene markers of tumor metastasis Ceased WO2006039671A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/954,495 2004-09-29
US10/954,495 US20070092881A1 (en) 2003-07-10 2004-09-29 Gene markers of tumor metastasis
US10/955,192 2004-09-29
US10/955,192 US20050249666A1 (en) 2003-07-10 2004-09-29 Establishment of human cancer cell lines with metastatic potential using NOD/SCID

Publications (3)

Publication Number Publication Date
WO2006039671A2 WO2006039671A2 (en) 2006-04-13
WO2006039671A9 WO2006039671A9 (en) 2006-06-29
WO2006039671A3 true WO2006039671A3 (en) 2006-10-12

Family

ID=35546587

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/035565 Ceased WO2006039678A2 (en) 2004-09-29 2005-09-29 Establishment of highly metastatic cell lines using nog mice
PCT/US2005/035539 Ceased WO2006039671A2 (en) 2004-09-29 2005-09-29 Gene markers of tumor metastasis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/035565 Ceased WO2006039678A2 (en) 2004-09-29 2005-09-29 Establishment of highly metastatic cell lines using nog mice

Country Status (2)

Country Link
JP (1) JP2008514205A (en)
WO (2) WO2006039678A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125384B2 (en) * 2007-10-18 2015-09-08 Riken Mouse having human leukemic stem cell and leukemic non-stem cell amplified therein, and method for production thereof
JP5568807B2 (en) * 2008-06-06 2014-08-13 静岡県 Identification of melanoma markers using proteomic analysis
US11536713B2 (en) 2009-12-25 2022-12-27 Chugai Seiyaku Kabushiki Kaisha Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
JP6230789B2 (en) 2010-10-06 2017-11-15 中外製薬株式会社 Cancer stem cell population and method for producing the same
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
CN102841200A (en) * 2011-06-24 2012-12-26 中国科学院上海药物研究所 Use of pIgR as molecular marker of early recurrence and/or metastasis of tumor and intervening target spot of anti-tumor metastasizing medicine
US10018630B2 (en) 2011-09-07 2018-07-10 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
JP6291254B2 (en) 2011-10-28 2018-03-14 中外製薬株式会社 Cancer stem cell specific molecule
CN103898205B (en) * 2013-05-07 2016-04-27 上海良润生物医药科技有限公司 The application of CST1
CN103941016B (en) * 2013-05-07 2016-04-27 上海良润生物医药科技有限公司 The use in conjunction of CST1 and carcinomebryonic antigen
CN108135150B (en) * 2015-06-16 2022-08-23 杰克逊实验室 Genetically modified non-human animals and methods involving complement dependent cytotoxicity
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013682A2 (en) * 2003-07-10 2005-02-17 Central Institute For Experimental Animals Animal model for the analysis of tumor metastasis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3753321B2 (en) * 2000-12-01 2006-03-08 財団法人実験動物中央研究所 Method for producing mouse suitable for engraftment, differentiation and proliferation of heterologous cells, mouse produced by the method and use of the mouse

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013682A2 (en) * 2003-07-10 2005-02-17 Central Institute For Experimental Animals Animal model for the analysis of tumor metastasis

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Affimetrix GeneChip Human Genome U133 Array Set HG-U133A", GEO, 11 March 2002 (2002-03-11), XP002254749 *
ANONYMOUS: "ATLAS GLASS HUMAN 1.0 MICROARRAY", CLONTECHNIQUES, April 2000 (2000-04-01), pages 1, XP002324248 *
CHINN ANNA M ET AL: "Identification of two novel ACTH-responsive genes encoding manganese-dependent superoxide dismutase (SOD2) and the zinc finger protein TIS11b (tetradecanoyl phorbol acetate (TPA)-inducible sequence 11b)", MOLECULAR ENDOCRINOLOGY, vol. 16, no. 6, June 2002 (2002-06-01), pages 1417 - 1427, XP002365894, ISSN: 0888-8809 *
LANLADO M E ET AL: "EXPRESSION AND FUNCTIONAL ANALYSIS OF VOLTAGE-ACTIVATED NA+ CHANNELS IN HUMAN PROSTATE CANCER CELL LINES AND THEIR CONTRIBUTION TO INVASION IN VITRO", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 4, no. 150, April 1997 (1997-04-01), pages 1213 - 1221, XP008002039, ISSN: 0002-9440 *
QIU YAN ET AL: "Targets of 17beta-oestradiol-induced apoptosis in colon cancer cells: a mechanism for the protective effects of hormone replacement therapy?", JOURNAL OF ENDOCRINOLOGY, vol. 181, no. 2, May 2004 (2004-05-01), pages 327 - 337, XP002365893, ISSN: 0022-0795 *
SHIMADA HIROYUKI ET AL: "Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: Overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 96, no. 2, 15 July 2000 (2000-07-15), pages 655 - 663, XP002222767, ISSN: 0006-4971 *
SMITH P ET AL: "Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 423, no. 1, 13 February 1998 (1998-02-13), pages 19 - 24, XP004261853, ISSN: 0014-5793 *
TARBE N ET AL: "IDENTIFICATION OF RAT PANCREATIC CARCINOMA GENES ASSOCIATED WITH LYMPHOGENOUS METASTASIS", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 22, no. 4, July 2002 (2002-07-01), pages 2015 - 2028, XP009039609, ISSN: 0250-7005 *
WOJTOWICZ-PRAGA SLAWOMIR M ET AL: "Matrix metalloproteinase inhibitors", INVESTIGATIONAL NEW DRUGS, vol. 15, no. 1, 1997, pages 61 - 75, XP002365895, ISSN: 0167-6997 *

Also Published As

Publication number Publication date
WO2006039671A2 (en) 2006-04-13
WO2006039678A2 (en) 2006-04-13
JP2008514205A (en) 2008-05-08
WO2006039671A9 (en) 2006-06-29
WO2006039678A3 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
WO2009026605A3 (en) Set of tumour-markers
WO2006039671A3 (en) Gene markers of tumor metastasis
EP4249602A3 (en) Method of preparing libraries of template polynucleotides
MA28938B1 (en) PRODUCT MARKING, TRACKING AND AUTHENTICATION METHODS AND SYSTEMS
WO2008066925A3 (en) Traceability in a modelling environment
PL1766017T3 (en) Tumor specific antibody
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
IL190095A0 (en) Recurrent gene fusions in prostate cancer
PL1632926T3 (en) A label comprising a transponder and a system comprising a transponder
WO2005013682A3 (en) Animal model for the analysis of tumor metastasis
WO2003089580A3 (en) Cancer models
CA115145S (en) Ink cartridge
WO2009085196A8 (en) Methods and compositions for correlating genetic markers with prostate cancer risk
ITMO20030173A0 (en) PROCEDURE FOR OBTAINING A FERTILIZING PREPARATION SUPPLIER OF MICROELEMENTS AND PREPARATION SO OBTAINABLE.
GB2464417B (en) Security deterrent mark and methods of forming the same
CA115126S (en) Ink cartridge
WO2007112350A3 (en) Method of assessing the metastatic status of a primary tumor
DE602005003734D1 (en) Magnetic Stripe Reader
CA115127S (en) Ink cartridge
GB0404933D0 (en) Magnetic marker for use in product authentication, and detector for reading the marker
CA115124S (en) Ink cartridge
CA115123S (en) Ink cartridge
CA111973S (en) Index card style planner leaf
ZA200803021B (en) Recurrent gene fusions in prostate cancer
DE602004005650D1 (en) METHOD FOR CLASSIFYING THE GENE EXPRESSION STRENGTH IN LUNG CANCER TISSUE.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 7/8-8/8, DRAWINGS, ADDED

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05800957

Country of ref document: EP

Kind code of ref document: A2